Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited announced an upcoming webinar to discuss early efficacy results from their azer-cel Phase 1b trial for CAR T naïve lymphomas and their presentation at the 67th American Society of Hematology Annual Meeting. This initiative reflects Imugene’s commitment to advancing cancer treatment and engaging stakeholders, potentially strengthening its position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies that activate the immune system to treat and eradicate tumors. Their platform technologies aim to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than traditional monoclonal antibody therapies. Imugene’s pipeline includes the CAR T cell therapy azer-cel, targeting CD19 for blood cancers, and oncolytic virotherapy CF33 for various cancers. The company collaborates with international cancer experts and aims to transform cancer treatment globally.
YTD Price Performance: -70.99%
Average Trading Volume: 2,758,458
Technical Sentiment Signal: Sell
Current Market Cap: A$108M
Learn more about IMU stock on TipRanks’ Stock Analysis page.